Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesRegeneus Ltd

Regeneus Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.009 AUD 0.00(0%)
Last update at 2024-04-29T00:00:00Z
Market Cap
3.68M

Momentum Score

…

Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia. The company's platform technology includes Progenza, a multi-synergistic therapy, which has completed Phase I clinical trial for the treatment of osteoarthritis; and in pre-clinical stage to treat neuropathic pain. It also develops Sygenus that is in pre-clinical stage for the treatment of skin wound healing. The company was incorporated in 2007 and is headquartered in Paddington, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.01
Low
0.01
High
52 Week Price Range
0.00
Low
0.02
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.01
Dividend Yield
-
Revenue TTM
0.99M
Revenue Per Share
0.00
Gross Profit TTM
1.02M
Debt / Equity
-1.07
ROE
-355.20%
Net Debt
1.64M
ROCE
66.36%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -1.69M -4.31M 2.15M -1.07M -6.02M
Net income -1.69M -4.38M 2.15M -3.84M -5.75M
Selling general administrative 1.77M 2.78M 4.23M 3.70M 4.44M
Gross profit - - 7.96M 1.66M 0.03M
Reconciled depreciation - 0.02M 0.05M 0.07M 0.27M
Ebit -1.20M -4.24M 2.17M -0.78M -5.89M
Ebitda -3.09M -4.22M 2.23M -0.71M -5.62M
Depreciation and amortization - 0.02M 0.05M 0.07M 0.27M
Operating income -1.35M -4.24M 2.17M -0.78M -5.89M
Other operating expenses 0.03M 4.65M 5.53M 5.01M 6.87M
Interest expense 0.29M 0.07M 0.08M 0.27M 0.40M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.26M 0.00M 0.28M 0.34M 0.52M
Net interest income -0.29M -0.07M -0.08M -0.27M -0.38M
Income tax expense - 0.07M -0.18M 2.77M -0.27M
Total revenue 0.00M 0.00M 7.96M 1.66M 0.03M
Total operating expenses - 4.65M 5.53M 5.01M 6.87M
Total other income expense net -0.77M -0.06M -0.02M -0.29M -0.13M
Net income from continuing ops -3.38M -4.31M 2.15M -1.07M -6.02M
Net income applicable to common shares -1.69M -4.31M 2.76M -1.07M -6.02M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 0.71M 2.55M 5.26M 3.56M 2.54M
Intangible assets - - 0.00M 0.00M 0.00M
Other current assets 0.03M 0.03M 0.11M 0.02M 2.12M
Total liab 2.53M 1.48M 2.85M 3.70M 8.93M
Total stockholder equity -1.81M 1.07M 2.41M -0.13M -6.39M
Other current liab 0.08M 0.31M 0.18M 1.44M 7.34M
Common stock 38.62M 38.62M 38.29M 38.16M 31.08M
Capital stock 38.62M 38.62M 38.29M 38.16M 31.08M
Retained earnings -42.28M -38.95M -36.48M -38.72M -37.88M
Other liab - 0.00M 3.06M 0.05M 0.18M
Other assets - 1.75M - - 0.00M
Cash 0.30M 0.10M 3.79M 0.98M 0.26M
Total current liabilities 2.53M 1.48M 1.30M 3.63M 8.75M
Current deferred revenue - - - 0.53M -3.43M
Net debt 1.64M 0.91M -2.25M 0.14M 3.52M
Short term debt 1.95M 1.01M 0.01M 1.11M 3.78M
Short long term debt 1.95M 1.00M - 1.10M 3.78M
Short long term debt total 1.95M 1.01M 1.54M 1.12M 3.78M
Other stockholder equity 1.84M 1.41M 0.54M 2.23M 0.41M
Property plant equipment 0.00M 0.02M 0.03M 0.08M 0.15M
Total current assets 0.71M 0.79M 5.23M 3.48M 2.38M
Long term investments - 1.75M - - 0.00M
Net tangible assets -0.12M 1.07M 4.15M -0.13M -6.39M
Short term investments 0.00M 0.07M 0.57M 0.57M 0.60M
Net receivables 0.38M 0.56M 0.75M 1.90M 0.65M
Long term debt - - 1.53M - -
Inventory 0.00M 0.04M - 0.01M 0.01M
Accounts payable 0.50M 0.16M 1.11M 0.56M 1.06M
Accumulated other comprehensive income 1.84M 1.41M 0.60M 0.43M 0.41M
Common stock total equity - - - 38.16M 31.08M
Non currrent assets other - - - - 0.16M
Non current assets total 0.00M 1.77M 0.03M 0.08M 0.16M
Capital lease obligations - 0.01M 0.01M 0.02M -
Long term debt total 0.00M 0.00M 0.01M 0.01M 0.00M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.05M -0.01M -0.01M -0.03M -0.03M
Change to liabilities -0.01M -0.71M -1.36M 0.73M 1.28M
Total cashflows from investing activities -0.05M -0.01M -0.01M 0.02M -0.01M
Net borrowings 0.95M 1.19M -1.10M -1.25M 2.78M
Total cash from financing activities 0.92M -0.10M 0.40M 2.63M 2.78M
Change to operating activities 0.27M 0.22M -0.31M 1.31M 0.24M
Net income -3.38M -4.38M 2.15M -1.09M -5.75M
Change in cash 0.21M -3.70M 2.81M 0.73M -0.84M
Begin period cash flow 0.10M 3.79M 0.98M 0.26M 1.09M
End period cash flow 0.30M 0.10M 3.79M 0.98M 0.26M
Total cash from operating activities -0.66M -4.36M 2.42M -1.92M -3.61M
Issuance of capital stock - - 1.50M 3.88M -
Depreciation 0.01M 0.02M 0.05M 0.07M 0.27M
Other cashflows from investing activities -0.05M - 0.00M 0.02M -
Change to inventory - - - 0.01M 0.01M
Change to account receivables 0.11M -0.10M 1.47M -1.47M -1.47M
Sale purchase of stock -0.03M - 0.00M 3.88M -
Other cashflows from financing activities 0.95M 1.16M -0.01M 0.05M 4.66M
Change to netincome 0.64M 1.29M -0.19M -1.51M 0.62M
Capital expenditures 0.00M 0.01M 0.01M 0.01M 0.01M
Change in working capital 1.08M 0.83M 0.57M 1.54M 2.38M
Other non cash items - 4.36M -2.15M 1.00M 5.75M
Free cash flow -0.66M -4.37M -0.01M -1.92M -0.01M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
RGS
Regeneus Ltd		 -
-%		 0.01 - - 3.72 3.14 6.79 132.14
CSL
CSL Ltd		 2.86
1.42%		 204.54 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.32
2.28%		 13.70 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -0.30
1.25%		 23.66 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.07
3.69%		 1.96 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Regeneus Ltd

Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia. The company's platform technology includes Progenza, a multi-synergistic therapy, which has completed Phase I clinical trial for the treatment of osteoarthritis; and in pre-clinical stage to treat neuropathic pain. It also develops Sygenus that is in pre-clinical stage for the treatment of skin wound healing. The company was incorporated in 2007 and is headquartered in Paddington, Australia.

16 Goodhope Street, Paddington, NSW, Australia, 2021

61 1300 995 098

https://regeneus.com.au

Name Title Year Born
Mr. Karolis Rosickas Chief Exec. Officer NA
Prof. Graham Vesey Ph.D. Chief Scientific Officer & Exec. Director 1965
Dr. Charlotte Morgan Ph.D. Head of R&D NA
Ling Leung Hang Company Sec. NA
Mr. Karolis Rosickas Chief Executive Officer NA
Prof. Graham Vesey Ph.D. Chief Scientific Officer & Executive Director 1965
Dr. Charlotte Morgan Ph.D. Head of Research & Development NA
Ling Leung Hang Company Secretary NA
Mr. Karolis Rosickas Chief Executive Officer NA
Prof. Graham Vesey Ph.D. Chief Scientific Officer & Executive Director 1965

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…